Hologic, Inc. (HOLX) Shares Bought by KBC Group NV

KBC Group NV boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 14.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,783 shares of the medical equipment provider’s stock after buying an additional 4,928 shares during the period. KBC Group NV’s holdings in Hologic were worth $1,460,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Grove Bank & Trust increased its stake in Hologic by 115.8% during the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 1,535 shares during the period. Hall Laurie J Trustee increased its stake in Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 225 shares during the period. Commonwealth Bank of Australia increased its stake in Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 600 shares during the period. MPS Loria Financial Planners LLC purchased a new stake in Hologic during the second quarter worth about $191,000. Finally, National Asset Management Inc. purchased a new stake in Hologic during the second quarter worth about $203,000. Hedge funds and other institutional investors own 98.08% of the company’s stock.

Shares of Hologic, Inc. (NASDAQ:HOLX) opened at $43.57 on Wednesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. Hologic, Inc. has a one year low of $35.76 and a one year high of $46.80. The firm has a market cap of $12,080.00, a P/E ratio of 21.13, a P/E/G ratio of 2.06 and a beta of 0.95.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The firm had revenue of $802.90 million for the quarter, compared to analyst estimates of $792.54 million. During the same period in the prior year, the firm earned $0.52 earnings per share. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. analysts predict that Hologic, Inc. will post 2.12 EPS for the current fiscal year.

A number of analysts have issued reports on HOLX shares. Royal Bank of Canada reiterated a “hold” rating and set a $42.00 price target on shares of Hologic in a research note on Friday, September 22nd. Needham & Company LLC reiterated a “buy” rating and set a $50.00 price target on shares of Hologic in a research note on Monday, October 2nd. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Stifel Nicolaus reiterated a “buy” rating and set a $45.00 price target (down from $48.00) on shares of Hologic in a research note on Monday, October 9th. Finally, Jefferies Group reiterated a “buy” rating and set a $44.00 price target (down from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $47.86.

In related news, Director Lawrence M. Levy sold 9,596 shares of the company’s stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. Insiders have sold 28,833 shares of company stock worth $1,107,270 over the last 90 days. Insiders own 0.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Hologic, Inc. (HOLX) Shares Bought by KBC Group NV” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2017/12/13/hologic-inc-holx-shares-bought-by-kbc-group-nv.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply